Novo Nordisk says completes hemophilia drug trial COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Friday it had completed the first phase III trial of a hemophilia drug, N9-GP. Novo Nordisk said in a statement that in patients given the drug, 99 percent of bleeding episodes were treated with only one infusion and two-thirds of the patients had experienced complete resolution of bleeding. Patients had also reported an improvement in quality of life during the trial and the drug appeared to have a safe and well-tolerated profile, Novo said in the statement. Reporting by Copenhagen Newsroom; Editing by Anthony Barker